Prevention of C5 activation ameliorates spontaneous and experimental factor H-deficient glomerulonephritis in mice

被引:129
作者
Pickering, M. C.
Warren, J.
Rose, K. L.
Carlucci, F.
Wang, Y.
Walport, M. J.
Cook, H. T.
Botto, M.
机构
[1] Univ London Imperial Coll Sci Technol & Med, Fac Med, Rheumatol Sect, London W12 0NN, England
[2] Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Histopathol, London W12 0NN, England
[3] Alex Pharmaceut Inc, Cheshire, CT USA
[4] Wellcome Trust Res Labs, London NW1 2BE, England
基金
英国惠康基金;
关键词
complement; inflammation;
D O I
10.1073/pnas.0601094103
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Membranoproliferative glomerulonephritis (MPGN) type II (dense deposit disease) is an inflammatory renal disease characterized by electron-dense deposits and complement C3 on the glomerular basement membrane. There is no effective therapy. We investigated the role of C5 activation in a model of MPGN that develops spontaneously in complement factor H-deficient mice (Cfh(-/-)). At 12 months there was a significant reduction in mortality, glomerular cellularity, neutrophil numbers, and serum creatinine levels in Cfh(-/-) mice deficient in C5. Excessive glomerular neutrophil numbers, frequently seen in patients with MPGN during disease flares, were also observed in Cfh(-/-) mice after the administration of an antiglomerular basement membrane antibody. This exaggerated injurious phenotype was absent in Cfh(-/-) mice deficient in C5 but not in Cfh(-/-) mice deficient in C6, indicating a key role for C5 activation in the induction of renal lesions. Importantly, the renal injury was completely reversed in Cfh(-/-) mice pretreated with an anti-murine C5 antibody. These results demonstrate an important role for C5 in both spontaneous MPGN and experimentally induced nephritis in factor H-deficient mice and provide preliminary evidence that C5 inhibition therapy might be useful in human MPGN type II.
引用
收藏
页码:9649 / 9654
页数:6
相关论文
共 48 条
[11]   THE CHEMOTACTIC RECEPTOR FOR HUMAN-C5A ANAPHYLATOXIN [J].
GERARD, NP ;
GERARD, C .
NATURE, 1991, 349 (6310) :614-617
[12]  
HABIB R, 1975, KIDNEY INT, V7, P204, DOI 10.1038/ki.1975.32
[13]   A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration [J].
Hageman, GS ;
Anderson, DH ;
Johnson, LV ;
Hancox, LS ;
Taiber, AJ ;
Hardisty, LI ;
Hageman, JL ;
Stockman, HA ;
Borchardt, JD ;
Gehrs, KM ;
Smith, RJH ;
Silvestri, G ;
Russell, SR ;
Klaver, CCW ;
Barbazetto, I ;
Chang, S ;
Yannuzzi, LA ;
Barile, GR ;
Merriam, JC ;
Smith, RT ;
Olsh, AK ;
Bergeron, J ;
Zernant, J ;
Merriam, JE ;
Gold, B ;
Dean, M ;
Allikmets, R .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (20) :7227-7232
[14]   Complement factor H variant increases the risk of age-related macular degeneration [J].
Haines, JL ;
Hauser, MA ;
Schmidt, S ;
Scott, WK ;
Olson, LM ;
Gallins, P ;
Spencer, KL ;
Kwan, SY ;
Noureddine, M ;
Gilbert, JR ;
Schnetz-Boutaud, N ;
Agarwal, A ;
Postel, EA ;
Pericak-Vance, MA .
SCIENCE, 2005, 308 (5720) :419-421
[15]   Acute nephrotoxic serum nephritis in complement knockout mice: relative roles of the classical and alternate pathways in neutrophil recruitment and proteinuria [J].
Hebert, MJ ;
Takano, T ;
Papayianni, A ;
Rennke, HG ;
Minto, A ;
Salant, DJ ;
Carroll, MC ;
Brady, HR .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1998, 13 (11) :2799-2803
[16]   Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria [J].
Hill, A ;
Hillmen, P ;
Richards, SJ ;
Elebute, D ;
Marsh, JC ;
Chan, J ;
Mojcik, CF ;
Rother, RP .
BLOOD, 2005, 106 (07) :2559-2565
[17]   Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria [J].
Hillmen, P ;
Hall, C ;
Marsh, JCW ;
Elebute, M ;
Bombara, MP ;
Petro, BE ;
Cullen, MJ ;
Richards, SJ ;
Rollins, SA ;
Mojcik, CF ;
Rother, RP .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (06) :552-559
[18]   HEREDITARY PORCINE MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS TYPE-II IS CAUSED BY FACTOR-H DEFICIENCY [J].
HOGASEN, K ;
JANSEN, JH ;
MOLLNES, TE ;
HOVDENES, J ;
HARBOE, M .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 95 (03) :1054-1061
[19]  
Kaplan Mariana, 2002, Curr Opin Investig Drugs, V3, P1017
[20]  
Kilgore KS, 1996, AM J PATHOL, V149, P953